NovoCure Ltd (NVCR) stock
NVCRNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/3031% below fair value
$11.14−0.16 (-1.42%)
Close on Nov 17, 2026Market cap $1.30BP/E –Yield –
NovoCure cash
Cash and short-term investments held at the end of each period.
NovoCure's cash was $96.73M at Sep 30, 2026. For fiscal 2025 it was $93.55M, down 43.7% from the year before. Over ten years it grew -2.4% a year on average. The highest annual figure on record is $246.17M in fiscal 2020.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $93.55M | -43.7% |
| FY2024 | Dec 31, 2024 | $166.09M | -31.0% |
| FY2023 | Dec 31, 2023 | $240.82M | +107.9% |
| FY2022 | Dec 31, 2022 | $115.83M | -44.7% |
| FY2021 | Dec 31, 2021 | $209.61M | -14.9% |
| FY2020 | Dec 31, 2020 | $246.17M | +37.2% |
| FY2019 | Dec 31, 2019 | $179.42M | +25.7% |
| FY2018 | Dec 31, 2018 | $142.76M | +76.9% |
| FY2017 | Dec 31, 2017 | $80.72M | -19.3% |
| FY2016 | Dec 31, 2016 | $100.05M | -16.3% |
| FY2015 | Dec 31, 2015 | $119.51M | +107.4% |
| FY2014 | Dec 31, 2014 | $57.61M | -67.2% |
| FY2013 | Dec 31, 2013 | $175.89M | +404.1% |
| FY2012 | Dec 31, 2012 | $34.89M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $96.73M | -71.7% |
| Q2 FY2026 | Jun 30, 2026 | $103.62M | -31.9% |
| Q1 FY2026 | Mar 31, 2026 | $97.32M | -24.8% |
| Q4 FY2025 | Dec 31, 2025 | $93.55M | -43.7% |
| Q3 FY2025 | Sep 30, 2025 | $342.12M | +84.5% |
| Q2 FY2025 | Jun 30, 2025 | $152.13M | -9.7% |
| Q1 FY2025 | Mar 31, 2025 | $129.43M | -71.7% |
| Q4 FY2024 | Dec 31, 2024 | $166.09M | -31.0% |
| Q3 FY2024 | Sep 30, 2024 | $185.42M | +19.7% |
| Q2 FY2024 | Jun 30, 2024 | $168.44M | +7.0% |
| Q1 FY2024 | Mar 31, 2024 | $457.36M | +145.1% |
| Q4 FY2023 | Dec 31, 2023 | $240.82M | +107.9% |
| Q3 FY2023 | Sep 30, 2023 | $154.86M | -36.5% |
| Q2 FY2023 | Jun 30, 2023 | $157.49M | -57.2% |
| Q1 FY2023 | Mar 31, 2023 | $186.64M | -2.6% |
| Q4 FY2022 | Dec 31, 2022 | $115.83M | -44.7% |
| Q3 FY2022 | Sep 30, 2022 | $243.81M | -64.7% |
| Q2 FY2022 | Jun 30, 2022 | $367.76M | +2.0% |
| Q1 FY2022 | Mar 31, 2022 | $191.63M | -41.2% |
| Q4 FY2021 | Dec 31, 2021 | $209.61M | -14.9% |
| Q3 FY2021 | Sep 30, 2021 | $690.69M | +193.4% |
| Q2 FY2021 | Jun 30, 2021 | $360.59M | +82.5% |
| Q1 FY2021 | Mar 31, 2021 | $325.98M | +78.4% |
| Q4 FY2020 | Dec 31, 2020 | $246.17M | +37.2% |
| Q3 FY2020 | Sep 30, 2020 | $235.38M | +12.0% |
| Q2 FY2020 | Jun 30, 2020 | $197.59M | +8.5% |
| Q1 FY2020 | Mar 31, 2020 | $182.71M | +18.5% |
| Q4 FY2019 | Dec 31, 2019 | $179.42M | +25.7% |
| Q3 FY2019 | Sep 30, 2019 | $210.17M | +67.9% |
| Q2 FY2019 | Jun 30, 2019 | $182.18M | +56.2% |
| Q1 FY2019 | Mar 31, 2019 | $154.16M | +35.5% |
| Q4 FY2018 | Dec 31, 2018 | $142.76M | +76.9% |
| Q3 FY2018 | Sep 30, 2018 | $125.16M | +48.6% |
| Q2 FY2018 | Jun 30, 2018 | $116.63M | +42.7% |
| Q1 FY2018 | Mar 31, 2018 | $113.76M | +32.1% |
| Q4 FY2017 | Dec 31, 2017 | $80.72M | -19.3% |
| Q3 FY2017 | Sep 30, 2017 | $84.23M | – |
| Q2 FY2017 | Jun 30, 2017 | $81.73M | – |
| Q1 FY2017 | Mar 31, 2017 | $86.12M | – |
| Q4 FY2016 | Dec 31, 2016 | $100.05M | – |
See a number that looks wrong?